Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone.
Atsushi NatsumeKosuke AokiFumiharu OhkaSachi MaedaMasaki HiranoAlimu AdilijiangKazuya MotomuraMinako SumiRyo NishikawaYoshitaka NaritaYoshihiro MuragakiTakashi MaruyamaTamio ItoTakaaki BeppuHideo NakamuraTakamasa KayamaShinya SatoMotoo NaganeKazuhiko MishimaYoko NakasuKaoru KurisuFumiyuki YamasakiKazuhiko SugiyamaTakanori OnishiYasuo IwadateMizuhiko TerasakiHiroyuki KobayashiAkira MatsumuraEiichi IshikawaHikaru SasakiAkitake MukasaTakayuki MatsuoHirofumi HiranoToshihiro KumabeNobusada ShinouraNaoya HashimotoTomokazu AokiAkio AsaiTatsuya AbeAtsuo YoshinoYoshiki ArakawaKenichiro AsanoKoji YoshimotoSoichiro ShibuiYusuke OkunoToshihiko Wakabayashinull nullPublished in: Journal of neuro-oncology (2020)
This additional sub-analytical study of JCOG0911 among patients with newly diagnosed GBM showed that tumor location at the temporal lobe, gross total resection, and MGMT promoter methylation were significant prognostic factors, although no factors specific to IFNβ addition were identified.